Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Sex Transm Dis ; 40(11): 865-9, 2013 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-24113409

RESUMEN

BACKGROUND: Trichomonas vaginalis is the most prevalent nonviral sexually transmitted infection in the United States, affecting 3.1% of women of reproductive age. Infection is associated with HIV acquisition and pelvic inflammatory disease. In the United States, Centers for Disease Control and Prevention guidelines recommend testing all women with vaginal discharge for T. vaginalis, but except for HIV-infected women, there are no national guidelines for screening asymptomatic persons. The objective of this analysis is to assess testing and screening practices for T. vaginalis among symptomatic and asymptomatic women in the sexually transmitted disease (STD) clinic setting. METHODS: We analyzed data on demographics, clinical presentation, and laboratory testing for all women visiting a clinician in 2010 to 2011 at any of 15 STD clinics participating in the STD Surveillance Network. Prevalence of laboratory-confirmed T. vaginalis infection was calculated among symptomatic women tested and among asymptomatic women screened. RESULTS: A total of 59,176 women visited STD clinicians: 39,979 were considered symptomatic and 19,197 were considered asymptomatic for T. vaginalis infection, whereas 211 were HIV-infected. Diagnostic practices varied by jurisdiction: 4.0% to 96.1% of women were tested or screened for T. vaginalis using any laboratory test. Among 17,952 symptomatic women tested, prevalence was 26.2%. Among 3909 asymptomatic women screened, prevalence was 6.5%. Among 92 HIV-infected women tested/screened, prevalence was 29.3%. CONCLUSIONS: Trichomoniasis is common among STD clinic patients. In this analysis, most STD clinics tested symptomatic women seeking care, in accordance with national guidelines. All HIV-infected women should be screened annually. Additional evidence and national guidance are needed regarding potential benefits of T. vaginalis screening in other asymptomatic women.


Asunto(s)
Infecciones por VIH/epidemiología , Enfermedad Inflamatoria Pélvica/epidemiología , Enfermedades de Transmisión Sexual/epidemiología , Vaginitis por Trichomonas/epidemiología , Trichomonas vaginalis/aislamiento & purificación , Adolescente , Adulto , Antiprotozoarios/uso terapéutico , Femenino , Infecciones por VIH/diagnóstico , Humanos , Persona de Mediana Edad , Nitroimidazoles/uso terapéutico , Enfermedad Inflamatoria Pélvica/diagnóstico , Factores de Riesgo , Enfermedades de Transmisión Sexual/diagnóstico , Vaginitis por Trichomonas/diagnóstico , Estados Unidos/epidemiología
2.
Emerg Infect Dis ; 18(6): 939-43, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22608054

RESUMEN

Nitroimidazoles (metronidazole and tinidazole) are the only recommended drugs for treating Trichomonas vaginalis infection, and previous samples that assessed resistance of such isolates have been limited in geographic scope. We assessed the prevalence of in vitro aerobic metronidazole and tinidazole resistance among T. vaginalis isolates from multiple geographic sites in the United States. Swab specimens were obtained from women who underwent routine pelvic examinations at sexually transmitted disease clinics in 6 US cities. Cultured T. vaginalis isolates were tested for nitroimidazole resistance (aerobic minimum lethal concentration [MLC] >50 µg/mL). Of 538 T. vaginalis isolates, 23 (4.3%) exhibited low-level in vitro metronidazole resistance (minimum lethal concentrations 50-100 µg/mL). No isolates exhibited moderate- to high-level metronidazole resistance or tinidazole resistance. Results highlight the possibility that reliance on a single class of antimicrobial drugs for treating T. vaginalis infections may heighten vulnerability to emergence of resistance. Thus, novel treatment options are needed.


Asunto(s)
Antibacterianos/farmacología , Farmacorresistencia Bacteriana , Metronidazol/farmacología , Enfermedades Bacterianas de Transmisión Sexual/microbiología , Vaginitis por Trichomonas/microbiología , Trichomonas vaginalis/efectos de los fármacos , Adolescente , Adulto , Anciano , Femenino , Humanos , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Vigilancia de Guardia , Enfermedades de Transmisión Sexual , Enfermedades Bacterianas de Transmisión Sexual/epidemiología , Vaginitis por Trichomonas/epidemiología , Trichomonas vaginalis/aislamiento & purificación , Estados Unidos/epidemiología , Adulto Joven
4.
Sex Transm Dis ; 39(1): 18-20, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22183839

RESUMEN

BACKGROUND: Criteria for diagnosis of male urethritis based on a Gram-stained smear (GSS) of urethral discharge were developed before the era of nucleic acid amplification testing (NAAT) for Neisseria gonorrhoeae (Ng) and Chlamydia trachomatis (Ct) and may be too stringent when considering the higher sensitivity of NAAT. OBJECTIVE: To evaluate Ct and Ng positivity at different strata of polymorphonuclear cells (PMN) per high power field (hpf) GSS microscopy. METHODS: A retrospective analysis of the electronic medical record system of the Denver Metro Health Clinic between March 1, 2005 and December 31, 2010; all men with a GSS test during this period had an NAAT for Ct and Ng and had GSS results recorded at 1 PMN/hpf increments. RESULTS: A total of 13,520 GSS were available for analysis. For Ct, a statistically significant trend was observed along the PMN/hpf incremental spectrum, and a significant increase in positivity was observed between the 1 and 2 PMN/hpf strata (from 6.5% to 16.2%). For men diagnosed with Ng, no such trend was observed, and >95% of GSS results fell in the >10 strata. A subanalysis to control for laboratory technician variance and difference in NAAT technology showed similar results. CONCLUSION: Our data support lowering the diagnostic criteria of the GSS diagnosis of male urethritis to ≥2 PMN/hpf. At this level, the Ct positivity (16.2%) is similar or higher than positivity in men who receive presumptive chlamydia treatment as a contact to patients diagnosed with gonorrhea, pelvic inflammatory disease, or mucopurulent cervicitis.


Asunto(s)
Infecciones por Chlamydia/diagnóstico , Chlamydia trachomatis/aislamiento & purificación , Gonorrea/diagnóstico , Neisseria gonorrhoeae/aislamiento & purificación , Uretritis/diagnóstico , Infecciones por Chlamydia/microbiología , Chlamydia trachomatis/genética , Colorado , Intervalos de Confianza , Registros Electrónicos de Salud , Violeta de Genciana , Gonorrea/microbiología , Humanos , Masculino , Neisseria gonorrhoeae/genética , Técnicas de Amplificación de Ácido Nucleico/métodos , Fenazinas , Estudios Retrospectivos , Enfermedades de Transmisión Sexual/diagnóstico , Enfermedades de Transmisión Sexual/microbiología
5.
Sex Transm Dis ; 37(4): 259-63, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20220562

RESUMEN

BACKGROUND: Notifying patients of gonorrhea and chlamydia test results using online services may improve clinic efficiency and increase receipt of test results. This study evaluated the implementation of an online results system in an urban sexually transmitted infections clinic. METHODS: Using the clinic's electronic medical records system to assess if and how gonorrhea and chlamydia test results were obtained, 3 time periods were examined between December 2007 and April 2009: period 1, six months before initiation of the online results system; Period 2, six months when patients could opt in for online results by creating their own access codes; and Period 3, four months when access codes were assigned. In addition, a survey was conducted to assess reasons for accepting or declining the online results system. RESULTS: A total of 9056 new patient visits were evaluated. During periods 1, 2, and 3, respectively 67%, 67%, and 70% patients received results either online or by telephone (NS). The proportion of patients calling the clinic for results decreased from 67% in period 1, to 51% in period 2, and 36% in period 3 (P < 0.0001). Survey results indicated that patients accepted online results primarily because of the ability to check results anytime of day. Reasons for not accepting results online included lack of Internet access or a preference to receive results via the telephone. CONCLUSIONS: The online results system decreased the number of phone calls to the clinic pertaining to STI test results, but had no effect on the overall proportion of patients receiving results.


Asunto(s)
Instituciones de Atención Ambulatoria , Infecciones por Chlamydia/epidemiología , Registros Electrónicos de Salud/estadística & datos numéricos , Gonorrea/epidemiología , Internet , Sistemas en Línea , Conducta Sexual/estadística & datos numéricos , Adolescente , Adulto , Infecciones por Chlamydia/diagnóstico , Trazado de Contacto , Femenino , Gonorrea/diagnóstico , Humanos , Masculino , Satisfacción del Paciente , Prevalencia , Evaluación de Programas y Proyectos de Salud , San Francisco/epidemiología , Encuestas y Cuestionarios , Población Urbana/estadística & datos numéricos
6.
Sex Transm Dis ; 36(3): 127-8, 2009 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-19174728

RESUMEN

BACKGROUND: Increased awareness of HIV serostatus is a cornerstone of HIV prevention efforts. Thus, routine HIV testing in clinical settings has been identified as a priority. We report on our experience with making rapid HIV testing a routine procedure in a large STI clinic. METHODS: A series of logistical changes were implemented to enhance HIV testing uptake, including introduction of rapid testing, changes in sequence of clinical procedures, and an opt-out consent process. The impact of these changes on HIV testing was measured by the ratio of HIV testing and syphilis RPR testing, with the latter defined as the gold standard of routine testing in an STI clinic setting. RESULTS: Over time and in relationship to the introduction of clinic changes, the HIV/RPR ratio increased from 0.79 at baseline to 0.96 after full implementation. Overall HIV positivity rates did not vary significantly over time. CONCLUSION: After the introduction of several changes in clinic procedures, we experienced an increase HIV testing uptake relative to routine syphilis testing. In STI clinics, HIV testing can be made as normal as other routine STI testing.


Asunto(s)
Serodiagnóstico del SIDA/estadística & datos numéricos , Instituciones de Atención Ambulatoria/estadística & datos numéricos , Infecciones por VIH/diagnóstico , Enfermedades de Transmisión Sexual/prevención & control , Población Urbana , Infecciones por VIH/prevención & control , Humanos , Tamizaje Masivo/estadística & datos numéricos , Aceptación de la Atención de Salud , Enfermedades de Transmisión Sexual/diagnóstico
7.
Obesity (Silver Spring) ; 27(12): 1975-1981, 2019 12.
Artículo en Inglés | MEDLINE | ID: mdl-31603630

RESUMEN

OBJECTIVE: The aim of this study was to examine the prescribing patterns and use of antiobesity medications in a large cohort of patients using data from electronic health records. METHODS: Pharmacy- and patient-level electronic health record data were obtained on 2,248,407 adults eligible for weight-loss medications from eight geographically dispersed health care organizations. RESULTS: A total of 29,964 patients (1.3% of total cohort) filled at least one weight-loss medication prescription. This cohort was 82.3% female, with median age 44.9 years and median BMI 37.2 kg/m2 . Phentermine accounted for 76.6% of all prescriptions, with 51.7% of prescriptions being filled for ≥ 120 days and 33.8% filled for ≥ 360 days. There was an increase of 32.9% in medication days for all medications in 2015 compared with 2009. Higher prescription rates were observed in women, black patients, and patients in higher BMI classes. Of 3,919 providers who wrote at least one filled prescription, 23.8% (n = 863) were "frequent prescribers" who wrote 89.6% of all filled prescriptions. CONCLUSIONS: Weight-loss medications are rarely prescribed to eligible patients. Phentermine accounted for > 75% of all medication days, with a majority of patients filling it for more than 4 months. Less than one-quarter of prescribing providers accounted for approximately 90% of all prescriptions.


Asunto(s)
Fármacos Antiobesidad/uso terapéutico , Atención a la Salud/organización & administración , Obesidad/tratamiento farmacológico , Pérdida de Peso/efectos de los fármacos , Adulto , Fármacos Antiobesidad/farmacología , Estudios de Cohortes , Femenino , Historia del Siglo XXI , Humanos , Masculino
8.
J Clin Virol ; 33(2): 172-5, 2005 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15911434

RESUMEN

BACKGROUND: Effective strategies to combat the spread of influenza viruses rely on accurate diagnosis of the infection, which is greatly affected by the sensitivity of the assays used. OBJECTIVES: To determine if the sensitivity of assays used to detect influenza varies with the viral strains. STUDY DESIGN: This prospective study used 142 respiratory specimens submitted to the clinical virology laboratory during the 2003/2004 influenza season, when the H3N2 Fujian strain was first detected in our community, to assess sensitivities of rapid immunoassay (RIA), shell-vial (SV), hemadsorption (HA)-, and fluorescent antibody (FA)-based conventional tissue culture (TC). Results were compared with similar evaluations performed in 2002/2003 or earlier seasons. RESULTS: Sensitivities of RIA, SV, HA-TC, and FA-TC were 44, 70, 82, and 100%, respectively for influenza virus circulating in 2003/2004. The comparison with results obtained in previous influenza seasons showed a significantly decreased sensitivity of HA-TC (p=0.02) and lower sensitivity of RIA but without reaching statistical significance (44% versus 72%, p=0.2). CONCLUSIONS: This report underscores the importance of determining the accuracy and sensitivity of diagnostic tests against emerging influenza variant strains.


Asunto(s)
Virus de la Influenza A , Gripe Humana/diagnóstico , Gripe Humana/virología , Antígenos Virales/análisis , Efecto Citopatogénico Viral , Técnica del Anticuerpo Fluorescente , Hemabsorción , Humanos , Inmunoensayo , Virus de la Influenza A/clasificación , Virus de la Influenza A/genética , Virus de la Influenza A/inmunología , Estudios Retrospectivos , Sensibilidad y Especificidad , Cultivo de Virus
9.
Sex Transm Dis ; 35(4): 336-40, 2008 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-18277943

RESUMEN

OBJECTIVE: To evaluate the use of a testing-only "express" visit option to enhance efficiency in a busy STI clinic. METHODS: At the Denver Metro Health Clinic, clients at low risk for sexually transmitted infections (STI) are offered an express visit comprised of a urine test for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) as well as optional syphilis and human immunodeficiency virus (HIV) testing, but no physical examination. Higher risk clients (STI-related symptoms, contact to STI, men having sex with men, injection drug use, exchange of sex for money or drugs) are offered a comprehensive visit that includes a physical examination. The triage system was evaluated for the period April 2005--July 2006 by comparing rates of CT, GC, syphilis, and HIV between the 2 visit options. RESULTS: Of 13,447 clients with new visits, 3284 (24.4%) were express visits. When compared with clients with comprehensive visits, express visit clients had lower rates of CT (8.1% vs. 17.2%), GC (0.9% vs. 7.4%), syphilis (0.7% vs. 1.2%), and HIV (0.1% vs. 0.2%). Of 2969 STI cases, only 10.8% were diagnosed among clients with express visits. Express visits resulted in a 39% time saving for men and a 56% for women. With the possible exception of asymptomatic urethritis among men, underdiagnosis of STI beyond CT, GC, syphilis, and HIV among express visit clients appeared to be low. CONCLUSION: The triage system at DMHC effectively selects clients at highest risk for STI and increases clinic efficiency.


Asunto(s)
Instituciones de Atención Ambulatoria/estadística & datos numéricos , Infecciones por Chlamydia , Gonorrea , Técnicas de Amplificación de Ácido Nucleico/métodos , Visita a Consultorio Médico/estadística & datos numéricos , Enfermedades de Transmisión Sexual/prevención & control , Serodiagnóstico del SIDA , Adulto , Infecciones por Chlamydia/diagnóstico , Infecciones por Chlamydia/tratamiento farmacológico , Infecciones por Chlamydia/epidemiología , Chlamydia trachomatis/aislamiento & purificación , Femenino , Gonorrea/diagnóstico , Gonorrea/tratamiento farmacológico , Gonorrea/epidemiología , Infecciones por VIH/diagnóstico , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/epidemiología , Humanos , Masculino , Neisseria gonorrhoeae/aislamiento & purificación , Prevalencia , Enfermedades de Transmisión Sexual/tratamiento farmacológico , Enfermedades de Transmisión Sexual/epidemiología , Enfermedades de Transmisión Sexual/etiología , Sífilis/diagnóstico , Sífilis/tratamiento farmacológico , Sífilis/epidemiología , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA